Gapping up
In reaction to earnings/guidance:
- ABCL +13.5%, BNTX +5.6%, ANGO +3.7%, MKC +3.2%
Other news:
- MBRX +15.7% (receives Fast Track Designation from FDA for Annamycin)
- FPI +7.6% (files for $300 mln mixed securities shelf offering)
- LYRA +5.9% (to present LANTERN phase 2 study results)
- QELL +5.3% (Lilium announces intention to list on Nasdaq through a merger with Qell Acquisition Corp)
- VIPS +5.2% (authorizes $500 mln share repurchase program over the 24-month period)
- JG +5% (has entered into a partnership agreement with the world's largest digital currency trading platform)
- TLSA +4.9% (provides plans for Phase 2 clinical study in moderate to severe Covid-19 patients)
- STOK +4.8% (announced the authorization of its CTA by the UKMHRA to initiate a Phase 1/2a study (ADMIRAL) of STK-001 for the treatment of Dravet syndrome)
- GSM +4.6% (has engaged with the European Works Council; GSM is seeking to reduce or cease production at some of its sites in Europe)
- GME +3.6% (appointed Elliott Wilke to the role of Chief Growth Officer - start date is April 5, 2021)
- CYDY +3.4% (CytoDyn's leronlimab decreased mortality at 14 days by 82% with statistically significant p-value of 0.0233 amongst critically ill COVID-19 patients)
- HZNP +2.8% (FDA has approved a prior approval supplement to the previously approved BLA giving Horizon authorization to manufacture more TEPEZZA drug product resulting in an increased number of vials with each manufacturing slot)
- MAXR +2.3% (announces delivery of Solar Electric Propulsion Chassis for NASA's Psyche mission)
- CUBI +2.2% (COO to step down)
- UFPI +2.1% (to acquire Walnut Hollow Farm)
- AMRN +2% (receives European Commission approval for VAZKEPA to reduce cardiovascular risk)
- PIRS +2% (Pieris Pharmaceuticals and AstraZeneca (AZN) amended non-exclusive Anticalin platform license agreement)
- DGII +1.6% (to acquire Haxiot)
- AKBA +1.6% (submits NDA to the FDA for Vadadustat)
- SLDB +1.5% (Suvretta Capital Mgmt discloses 5.4% stake)
- OSUR +1.1% (submits an application to the FDA for EUA of its COVID-19 rapid antigen test for both Prescription Home Use, and Professional Use in point of care (POC) settings)
Analyst comments:
- DXC +3.4% (upgraded to Buy from Hold at Deutsche Bank)
- YELP +2% (upgraded to Buy from Neutral at Citigroup)
- VIAC +1.7% (upgraded to Neutral from Underperform at Credit Suisse)
- TCBI +1.4% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- ECL +1.3% (upgraded to Buy from Hold at Deutsche Bank)
- OVV +1.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ROKU +1.2% (upgraded to Buy from Hold at Truist)